Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Vemurafenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Roche and KeChow Reach a Cooperation Agreement
    Roche and KeChow Reach a Cooperation Agreement

    20 Aug 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/roche-and-kechow-reach-a-cooperation-agreement-301358623.html

    PRNEWSWIRE
    20 Aug 2021
    Share Share
    FDA Approves Atezolizumab Plus Cobimetinib and Vemurafenib for Advanced Melanoma
    FDA Approves Atezolizumab Plus Cobimetinib and Vemurafenib for Advanced Melanoma

    30 Jul 2020

    // CANCERNETWORK

    https://www.cancernetwork.com/view/fda-approves-atezolizumab-plus-cobimetinib-and-vemurafenib-for-advanced-melanoma

    CANCERNETWORK
    30 Jul 2020
    Share Share
    Roche's Tecentriq, on top of targeted drugs, stalls melanoma
    Roche's Tecentriq, on top of targeted drugs, stalls melanoma

    26 Apr 2020

    // Carly Helfand FIERCE PHARMA

    https://www.fiercepharma.com/pharma/embargoed-roche-s-tecentriq-added-to-cotellic-and-zelboraf-stalls-melanoma-progression

    Carly Helfand FIERCE PHARMA
    26 Apr 2020
    Share Share
    Roche's phase III IMspire150 study of Tecentriq plus Cotellic & Zelboraf
    Roche's phase III IMspire150 study of Tecentriq plus Cotellic & Zelboraf

    13 Dec 2019

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=119938&sid=2

    PHARMABIZ
    13 Dec 2019
    Share Share
    HSE reimburses Braftovi combo
    HSE reimburses Braftovi combo

    23 Aug 2019

    // Anna Smith PHARMA TIMES

    http://www.pharmatimes.com/news/hse_reimburses_braftovi_combo_1298971

    Anna Smith PHARMA TIMES
    23 Aug 2019
    Share Share
    Meet the protein responsible for nearly $100B in cancer drug deals
    Meet the protein responsible for nearly $100B in cancer drug deals

    17 Aug 2019

    // Jacob Bell BIOPHARMADIVE

    https://www.biopharmadive.com/news/meet-the-protein-responsible-for-nearly-100b-in-cancer-drug-deals/561097/

    Jacob Bell BIOPHARMADIVE
    17 Aug 2019
    Share Share